Skip to content

Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.

Featured In Oncology

The PARADIGM study compared intensive induction chemotherapy (IC) to a novel combination therapy, azacitidine and venetoclax (aza-ven), in patients newly diagnosed with acute myeloid leukemia and eligible for IC. Results showed that aza-ven clearly outperformed IC in patients enrolled on study.

Featured In Cardiovascular

Gregory D. Lewis, MD, and colleagues recommend measuring time to VO2 recovery of 12.5% after cardiopulmonary exercise testing of patients with dyspnea on exertion, showing that this metric closely reflects cardiac-specific performance and predicts heart failure outcomes.

Featured In Otolaryngology

A study comparing gene therapy and cochlear implants found comparable or improved outcomes, while new research in mouse models highlights potential treatments for late-onset genetic deafness.

Featured In Endocrinology

Massachusetts General Hospital research indicates that more Americans have obesity based on new obesity classification that uses BMI and anthropometric measurements.

Featured In Orthopaedics

Orhun Muratoglu, PhD, Ebru Oral, PhD, and their team are developing a gentamicin-containing polyethylene material to deliver localized antibiotics for total joint replacements. Their goal is to reduce periprosthetic joint infections and improve the outcomes of two-stage revision surgeries, the current standard of care.

The Latest Oncology Advances

Adam S. Feldman, MD, MPH, Andrew Gusev, MD, and colleagues, are the first to show that prostate-specific antigen density retains significant prognostic value after diagnosis of prostate cancer, with values ≥0.15 ng/mL2 at any point during active surveillance nearly quadrupling the risk of biopsy grade progression.

Liron Bar-Peled, PhD, and colleagues have determined that mitochondrial function is pivotal to chemotherapy response and may help identify tumors that are sensitive to subtypes of chemotherapeutic agents.

Contributing Physicians

Vice Chair of Research, Department of Surgery, Massachusetts General Hospital, Section Head, Melanoma and Sarcoma Surgery Programs, Surgical Director, Termeer Center for Targeted Therapies, Mass General Brigham Cancer Institute

Director, Cellular Immunotherapy Program, Mass General Brigham Cancer Institute, Associate Professor of Medicine, Harvard Medical School

Marcela Maus, MD, PhD, Profile Image

Advances Specialties

Neuroscience

Investigators at Mass General Brigham found that stress-related brain activity may explain the increased risk of heart disease with depression and anxiety.

Orthopaedics

Could a minimally invasive procedure ease chronic musculoskeletal pain? Yan Epelboym, MD, MPH, discusses the promise of trans-arterial embolization.

Education & Training Opportunities

May 9, 2025

The Midlife Women's Health 2025 course is led by a multidisciplinary group of experts from Massachusetts General Hospital who will present on the evaluation and management of osteoporosis, gastrointestinal malignancy, stress, obesity, substance use disorder, anxiety, sexual dysfunction, breast cancer, and menopausal hormone therapy to assist clinicians in caring for their midlife patients.

Clinical Trials

In Neuroscience

The study involves multiple visits over 6 months. You will complete an 8-week stress reduction treatment that includes a medical device worn in the ear and attend MRI and PET scans. You will also complete daily migraine diaries online.

In Cardiovascular

The purpose of this research study is to learn about the effects of stress on the brain and disease of the heart and blood vessels (cardiovascular disease or CVD).